FDA’s Abortion Pill Mail-Order Decision Faces Scientific Scrutiny
Researchers criticize FDA’s 2021 decision to allow mail-order abortion pills as lacking real-world evidence.
2 min read
A recent study by the Charlotte Lozier Institute has cast doubt on the FDA’s 2021 decision to allow the abortion pill mifepristone to be mailed without an in-person appointment. The researchers argue the decision relied on flawed evidence and failed to meet scientific standards, raising serious concerns about patient safety.
Flawed Evidence Undermines FDA Decision
The study, published in Issues in Law and Medicine, highlights that the FDA’s review process for the drug’s Risk Evaluation and Mitigation Strategy (REMS) did not account for real-world conditions or adequately consider adverse impact reporting. The researchers found that the FDA’s reliance on studies that included in-person exams and ultrasounds was inconsistent with the new mail-order model, which lacks such safeguards.
Dr. Ingrid Skop, a co-author of the study, emphasized that the FDA’s decision should be grounded in real-world data. ‘When federal agencies remove regulations designed to safeguard patient health, those decisions should be grounded in evidence that reflects real-world practice,’ she said. ‘Our analysis found that the FDA’s review fell well short of that standard.’
Pro-Life Stakeholders Underrepresented
The scholars also pointed out that pro-life stakeholders were disproportionately underutilized and underacknowledged in the review process. They argued that the FDA gave more credence to pro-abortion groups, such as the National Abortion Federation, which influenced the review in ways that raised questions about the scientific basis of the decision.
Zachary Sluzala, another co-author, noted that the FDA’s reliance on studies that do not generalize to real-world conditions and complication reporting systems with significant limitations cast doubt on the agency’s justification for removing in-person dispensing requirements.
Medical and Legal Implications
Since the overturning of Roe v. Wade, medication abortions have become the most common method of ending an unborn child’s life. The decision to allow mail-order abortions has led to increased access to the drug in states where it is technically illegal. Critics argue that this has led to unsafe practices, including instances where women are advised to lie to doctors about their abortion if they seek treatment after complications.
The scholars call for the reinstatement of in-person dispensing requirements and a more robust system for tracking complications from the drug. They warn that the current approach risks undermining public health and patient safety.
Source: Daily Wire
